Press Room

Press Release / Jun 06, 2011

OSHA renews Hovione’s VPP STAR Certification

Top health and safety standards recognized

Loures, Portugal, June 6th, 2011 - Hovione announced today that its Technology Transfer Centre in New Jersey, USA, has achieved renewed membership in the prestigious "Star" Voluntary Protection Program (VPP) of the U.S. Department of Labor's Occupational Safety and Health Administration (OSHA). In communicating this renewal Robert D. Kulick, Regional Administrator of OSHA, indicated: “VPP participants serve as models for other employers and workers by operating excellent safety and health management programs. Achieving a level of worker protection that goes beyond compliance with government regulations is commendable”.

Being a Star participant in the Voluntary Protection Program means that the site is removed from the roster of OSHA inspections and that it opens its doors to others that may want to learn from the site’s practices.

“Hovione’s strategy is to stay ahead of requirements in every area of compliance – we do this because we have a genuine quality culture, we adopt best practices and we aim high. Quality and GMP compliance, health, safety and the environment – all rank high in our priorities. Our compliance record is something we are proud of. I also believe this gives comfort to our customers that we are the right home for their products” said Guy Villax, Chief Executive.

Hovione is a leading contract manufacturer that stands behind at least one NDA approval every year. In 2010 Hovione made clinical trial materials for over 60 different compounds, and supplied over 30 commercial APIs made in its sites.

About Hovione

Hovione is an international company with over 50 years’ experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the U.S., China, Ireland, and Portugal, the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit the Hovione site at www.hovione.com  or contact: 

Marketing & Communication, Isabel Pina, + 351 21 982 9362, e-mail: ipina@hovione.com .

 

 

Also in the Press Room

See All

Continuous Tableting (CT) is defined as continuous manufacturing of oral dose drugs, specifically tablets. As per ICH's Q13 definition1, a continuous manufacturing process in the pharmaceutical industry comprises at least two unit operations integrated from a mechanical and software perspective. There is a wide combination of possible CT process configurations that are dependent on the needs of the intended product formulation and each of the individual unit operations that constitute the process train can be continuous, semi-continuous, or batch processes. The typical manufacturing processes for tablet formulation are direct compression (DC), dry granulation (DG) and wet granulation (WG)2 - details on these manufacturing processes are beyond the scope of this article, so the interested reader is directed to relevant literature. The actual implementation of CT technology in a facility can broadly vary depending on the level of desired integration and automation. Process trains can be designed to be flexible and converted between multiple configurations (e.g. continuous DC, DG and WG), controlled by the end user from one single software and within a single clean room. The other possibility would be for subsections of the CT process to be divided into multiple clean rooms where inprocess materials are transferred between suites via a bin-to-bin approach (e.g. a granulation suite to prepare granules from raw materials followed by continuous DC (CDC) to blend the granules and produce tablets). The level of automation and instrumentation designed into the CT process (typically involving Process Analytical Technologies, PAT) can open the possibility to implement sophisticated control strategies. Key components of a control strategy that need to be considered for CT are material tracking and genealogy, knowledge of the residence time distribution (RTD), and in-process controls (spectroscopic and/or soft sensors based on process parameters). Holistically, these control strategy elements enable the implementation of a material diversion strategy to automatically divert out of specification material from the process. In their most advanced form, control strategies may also enable real time release testing (RTRt) of the final tablet drug product and reduce the off-line analytical burden and the number of operators needed to manage the process.   Read the full article at gmp-journal.com  

Article

Continuous Tableting and the Road to Global Adoption

Mar 04, 2024